India calls for more predictable regulatory environment in Brazil to boost pharma exports
India called for a more predictable regulatory environment in Brazil to help boost Indian pharmaceutical exports to the country.
India and Brazil agreed to work toward early finalisation of the Terms of Reference for negotiations to expand the scope of the existing trade pact between India and the South American bloc Mercosur.
The discussion took place within a structured bilateral trade dialogue mechanism between the two countries.
Pharmaceuticals were flagged as a priority sector where non-tariff, regulatory barriers — rather than tariffs alone — are seen as the main constraint on India's export growth to Brazil.
Trade Agreement Typology: PTA vs FTA vs CEPA
Trade agreements exist on a spectrum of depth. A Preferential Trade Agreement (PTA) uses a "positive list" — tariff concessions apply only to specifically listed tariff lines, and coverage is limited. A Free Trade Agreement (FTA) instead uses a "negative list" — duties are eliminated on substantially all trade, with only a limited list of exclusions. A Comprehensive Economic Partnership/Cooperation Agreement (CEPA/CECA) goes further still, covering not just goods but services, investment, and regulatory cooperation. The current India-Mercosur pact is a PTA — the shallowest of these categories — which is precisely why both sides are now discussing "expanding the scope" of the agreement.
The agreement to finalise "Terms of Reference" for expanding the pact is the first formal step toward upgrading the shallow, 450-line PTA into a broader agreement — a template India has followed in past upgrades of narrow trade pacts into deeper CEPAs.
Non-Tariff Barriers: Regulatory Predictability in Pharma Trade
Beyond tariffs, "non-tariff barriers" (NTBs) — including divergent drug approval processes, inspection requirements, and technical/sanitary standards — are frequently cited by exporters as bigger obstacles to market access than customs duties. In pharmaceuticals specifically, each importing country's national regulator (in Brazil's case, ANVISA — Agência Nacional de Vigilância Sanitária) must separately approve products, inspect facilities, and certify compliance, creating duplication and delay when standards or timelines are unpredictable.
Key Details
- India is often termed the "pharmacy of the world," supplying roughly 20% of global generic medicine volumes (about 40% of US generic drug consumption) and around 60% of global vaccine production.
- India accounts for a significant share of WHO-prequalified Active Pharmaceutical Ingredients (APIs), reflecting the scale of its regulatory track record with the World Health Organization.
- India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), operates under the Drugs and Cosmetics Act, 1940, and signed a Memorandum of Understanding with Brazil's ANVISA in February 2026 aimed at regulatory cooperation and convergence in pharmaceutical/medical-product standards.
- Under WTO rules, such measures fall broadly within the Agreement on Technical Barriers to Trade (TBT) and the Sanitary and Phytosanitary (SPS) Agreement, which permit countries to set health/safety standards provided they are transparent, science-based, and not disguised protectionism.
India's call for "predictable" Brazilian regulation targets exactly this category of non-tariff friction — the CDSCO-ANVISA MoU is the institutional mechanism meant to convert ad hoc, case-by-case regulatory uncertainty into a more rules-based, mutually recognised approval pathway.
India's Institutional Trade Diplomacy Toolkit
India maintains a layered set of bilateral mechanisms below the level of formal trade negotiations — Joint Trade Committees, Trade Monitoring Mechanisms, and sector-specific working groups — that allow incremental resolution of market-access issues even while a comprehensive agreement remains under negotiation. These forums typically operate at the Commerce/Trade Secretary level and meet periodically to review trade trends and flag specific barriers.
Key Details
- Such institutional dialogues are common tools in India's economic diplomacy, distinct from the political/ministerial-level Joint Commission meetings that typically cover the full bilateral relationship.
- India-Brazil bilateral trade reached USD 15.07 billion in 2025-26, against a stated target of USD 30 billion by 2030 — implying the relationship must roughly double within the coming years.
- India-Mercosur bloc-wide trade reached USD 20.84 billion in 2025, underscoring that Brazil (the bloc's largest economy) is the primary driver of India's Mercosur trade relationship.
The regulatory and PTA-expansion asks discussed are the concrete deliverables typically generated through these lower-tier institutional mechanisms, which function as the working-level machinery behind headline trade targets like the USD 30-billion 2030 goal.
- India-Mercosur PTA: signed 2004, in force since June 1, 2009; covers ~450 tariff lines; requires 40% domestic value addition under its Rules of Origin.
- Mercosur members: Argentina, Brazil, Paraguay, Uruguay (Venezuela suspended).
- India-Brazil bilateral trade: USD 15.07 billion in 2025-26; target USD 30 billion by 2030.
- India-Mercosur bloc-wide trade: USD 20.84 billion in 2025.
- CDSCO-ANVISA regulatory cooperation MoU: signed February 2026.
- India supplies approximately 20% of global generic medicine volumes and around 60% of global vaccine production.